Emerging Company Profile
Ranok: a chaperone-based approach to targeted degradation
Emerging Company Profile: Ranok has raised $40M to test whether alternative to PROTACs could have safety, dosing advantages
Hangzhou-based Ranok has raised $40 million to test whether its alternative to PROTACs could have safety and dosing advantages.
Aug 18, 2021 | 8:43 PM GMT
An investor syndicate is backing